Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-blind, Placebo Controlled, Parallel-group, International Multicenter Phase III Trial of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection

NCT01402908 is registered in ClinicalTrials.gov with Cellxpert Biotechnology Corp. as lead sponsor.

NCT NCT01402908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01402908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-blind, Placebo Controlled, Parallel-group, International Multicenter Phase III Trial of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
Lead sponsor
Cellxpert Biotechnology Corp.
Phase
Phase 3
Overall status
Terminated
Start date
August 31, 2011
Completion date
January 31, 2015
Enrollment
520 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, hepatocellular carcinoma, liver cancer